ADC Trials to Watch at ASCO 2026: A Patient Preview
ASCO is where Phase 3 readouts land. Here's what's maturing into ASCO 2026 (May 29 – June 2, Chicago) on the antibody-drug conjugate side — and what patients seeking trials should be asking before the talks drop.
- DESTINY-Breast09 — trastuzumab deruxtecan + pertuzumab vs THP as 1L HER2-positive metastatic breast cancer. Rapid Oral Abstract #1021. Phase III; n=1,157.
- TROPION-Breast02 — datopotamab deruxtecan (Datroway) as 1L locally recurrent inoperable or metastatic TNBC in PD-(L)1-ineligible patients. Oral Abstract. FDA approval for this indication landed May 22, 2026 based on this trial.
- DESTINY-PanTumor02 (bladder cohort) — trastuzumab deruxtecan in pretreated HER2-expressing urothelial cancer. Final Part 1 results presented at ASCO GU 2026 (overall ORR 39.0%; 56.3% in IHC 3+ tumors, 35.0% in IHC 2+); updated data possible at the main ASCO meeting.
More abstracts will be confirmed as sponsor portfolio press releases are published in the days leading up to the May 31 LBA release date.
Why ASCO 2026 Matters for ADC-Trial Patients
The American Society of Clinical Oncology (ASCO) Annual Meeting is the largest oncology conference of the year. Where AACR (held April 17–22, 2026 in San Diego) showcased earlier-stage research and novel drug designs, ASCO is where Phase 3 confirmatory data lands — the readouts that change FDA approvals, the trials that change first-line standards, the registrational datasets that move drugs from "promising" to "available." For patients, ASCO timing matters because:
- New FDA-approved options often follow ASCO data drops within weeks. Drugs presented at ASCO with positive Phase 3 results frequently receive approval that summer or fall.
- Trial-enrollment criteria shift after positive readouts. If a drug becomes standard-of-care in 1L, the post-1L trials reset to focus on that new backbone — eligibility and arm structures change.
- Combination trials get green-lit. Successful single-agent data at ASCO triggers immediate combo trial designs that open over the following months.
What's Different in 2026 vs Prior ASCOs
Three structural shifts in the ADC landscape going into ASCO 2026:
- EGFR-ADCs have matured. Going into ASCO 2026, MRG003 / Becotatug Vedotin and BL-B01D1 (EGFR × HER3 bispecific ADC) are in active Phase 3 trials in nasopharyngeal carcinoma and head-and-neck cancers. ASCO is where the first registrational-quality readouts from these regional Phase 3 trials are likely to be presented.
- ADC + checkpoint-immunotherapy combinations are entering 1L. Several Phase 3 trials combine an ADC with a PD-1 or PD-L1 inhibitor in previously-untreated metastatic cancer. The 2026 readouts move ADCs from late-line salvage into the front-line conversation.
- Bispecific ADC clinical data continues to expand. BL-B01D1 (EGFR × HER3 bispecific ADC, Sichuan Baili) is already the most clinically-advanced bispecific ADC, with Phase 3 trials across NSCLC, NPC, ESCC, and breast cancer; expect further data updates at ASCO 2026. AACR 2026 also showcased earlier-stage bispecific ADC designs (NEOK001, NEOK002, ATG-125, VBC108) moving toward Phase 1 / 2 starts.
ADC Readouts to Watch by Cancer Type
Nasopharyngeal Carcinoma (NPC)
NPC has emerged as one of the most active ADC-development settings in 2026. Going into ASCO:
- MRG003 / Becotatug Vedotin (EGFR-ADC) — multiple Phase 3 trials in different settings: combined with PD-1 + sintilimab in locoregionally-advanced NPC, used in recurrent/metastatic NPC after platinum, used in LA-NPC with suboptimal response to induction.
- BL-B01D1 (EGFR × HER3 bispecific ADC) + PD-1 in locally-advanced NPC — Phase 2 data progressing.
- HLX43 (PD-L1 ADC) in recurrent/metastatic NPC — Phase 2 readout possible.
What patients should ask: if you have recurrent/metastatic NPC after platinum, ADC trials are now multi-Phase 3. Eligibility shifts quickly as new lines of therapy become standard. See current recruiting NPC trials.
Breast Cancer (the headline ADC story this year)
Breast cancer is where the most-confirmed ASCO 2026 ADC abstracts sit. Two are already on the program:
- DESTINY-Breast09 (Rapid Oral Abstract #1021) — trastuzumab deruxtecan + pertuzumab vs THP (taxane + trastuzumab + pertuzumab) as first-line treatment for HER2-positive metastatic breast cancer. Phase III, n=1,157 patients with no prior chemotherapy or HER2-targeted therapy for metastatic disease. Headline result: 44% reduction in risk of disease progression or death, with median PFS 40.7 months vs 26.9 months with standard care. FDA approved this indication on December 15, 2025 — the first new frontline standard for HER2-positive MBC in a decade. ASCO 2026 presents the exploratory analysis of treatment duration and clinical outcomes.
- TROPION-Breast02 (Oral Abstract) — datopotamab deruxtecan (Datroway, TROP2 ADC) as first-line treatment for locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) in patients who are not candidates for PD-1/PD-L1 inhibitors. The FDA approved this indication on May 22, 2026 (the day before this preview was published), based on this Phase 3 trial — making Datroway the first TROP2-directed ADC for 1L metastatic TNBC. ASCO 2026 presents the underpinning data: a 43% reduction in progression/death risk vs chemotherapy and approximately 5-month median OS improvement.
Additional likely topics on the program based on the active Phase 3 trial landscape:
- HER2-ultra-low / HER2-zero T-DXd expansion data (DESTINY-Breast06 follow-up)
- T-DXd combinations with CDK4/6 inhibitors, immune-checkpoint inhibitors, or endocrine therapy
- Sacituzumab govitecan (Trodelvy) earlier-line readouts in HR-positive / HER2-negative metastatic breast cancer
- Datopotamab deruxtecan additional readouts in HR-positive metastatic disease (TROPION-Breast01 follow-up)
See current recruiting breast cancer trials.
Gastric and Gastroesophageal Cancer
HER2+ gastric cancer was where trastuzumab deruxtecan first received FDA approval after gastric-specific trials. ASCO 2026 watch:
- SHR-A1811 (anti-HER2 ADC) in previously-untreated HER2+ gastric/GEJ — Phase 3 first-line readout possible
- HER2-low gastric ADC data
- CLDN18.2 ADCs (AZD0901, IBI343, JS107) — AACR showcased earlier-phase data; ASCO is where the first Phase 2 expansion data lands
See current recruiting gastric cancer trials.
Lung Cancer (NSCLC and SCLC)
The lung-cancer ADC space has matured into multiple competing classes:
- B7-H3 ADCs — ifinatamab deruxtecan (I-DXd, Daiichi Sankyo) Phase 2/3 readouts in pretreated NSCLC and pretreated extensive-stage SCLC (the IDeate-PanTumor01 / IDeate-Lung01 platform). SCLC is where I-DXd has shown the strongest single-agent activity and is where the next confirmatory data is expected. Risvutatug rezetecan (HS-20093, Hansoh/GSK) is the other actively-developing B7-H3 ADC.
- HER3 ADCs (patritumab deruxtecan / HER3-DXd) in EGFR-mutant NSCLC after osimertinib progression
- TROP2 ADCs — datopotamab deruxtecan (Datroway), sacituzumab govitecan (Trodelvy), and sacituzumab tirumotecan (sac-TMT / MK-2870 / SKB264, Merck/Kelun) — first-line and post-checkpoint expansion data; see also the breast section above
- Risvutatug rezetecan + adebrelimab (B7-H3 ADC + PD-L1) — the 47.1% ORR and 14.0-month median PFS in advanced non-squamous NSCLC reported at AACR 2026 may have follow-up data
See NSCLC trials | See SCLC trials.
Cholangiocarcinoma
HER2-directed ADC activity in HER2-expressing biliary tract cancers centers on trastuzumab deruxtecan, often combined with chemotherapy or immunotherapy. (Note: zanidatamab is a naked HER2 × HER2 bispecific antibody, not an ADC; the ADC version, zanidatamab-zovodotin / ZW49, is at earlier development.) ASCO 2026 watch: T-DXd combination trial updates and Phase 2 expansion data in HER2-expressing biliary subsets. See cholangiocarcinoma trials.
Other Cancer Types
- Ovarian (platinum-resistant): CLDN6 ADCs (QLS5132) and FOLR1 ADC updates. Trials.
- Prostate (mCRPC): ARX517 (PSMA-targeted ADC, Ambrx/J&J; APEX-01 Phase 1/2 with early PSA declines and RECIST responses in heavily pretreated mCRPC) is the lead PSMA-ADC. STEAP1-ADC efforts (vandortuzumab vedotin, ABBV-969, ADRX-0405) have had a more challenging history; the STEAP1 space is now dominated by xaluritamig (a TCE, covered in the related TCE post). Note: the broader PSMA-prostate therapeutic field is currently dominated by radioligand therapy (Pluvicto / 177Lu-PSMA-617), not ADCs. Trials.
- Bladder/urothelial: Nectin-4 ADC (enfortumab vedotin) earlier-line expansion data. Trials.
- Colorectal (CRC): CDH17 ADCs and EGFR bispecific ADCs — early-phase clinical data. Trials.
- Merkel cell carcinoma: The MCC ADC pipeline is narrow — checkpoint inhibitors (avelumab) and the DLL3-targeting TCE tarlatamab dominate; antigen-rich subsets (B7-H3, somatostatin-receptor) carry the limited ADC interest. Trials.
ADC + Immunotherapy: The Front-Line Question
Perhaps the most consequential question going into ASCO 2026: do ADC + PD-1/PD-L1 combinations beat chemotherapy + PD-1/PD-L1 in front-line metastatic disease? Multiple Phase 3 trials across breast, lung, gastric, and head-and-neck cancers are testing exactly this comparison. Positive readouts would move ADCs from "after progression" to "from day 1" — a major shift in eligibility for downstream lines.
What patients should know:
- ADC + IO combinations in 1L are still trial-only in most diseases. If you're newly diagnosed with metastatic disease in a cancer with an active ADC-IO Phase 3 trial, ask your oncologist whether enrollment makes sense before starting standard 1L chemo-IO.
- Eligibility windows are narrow. Most 1L trials require minimal prior therapy. The strongest enrollment moment is right at diagnosis of metastatic disease, not after one or two cycles of chemo.
What This Means for Patients Seeking Trials
- Biomarker testing is the gate. Most 2026 ADC trials require specific marker confirmation on tumor tissue. The common tests are IHC (immunohistochemistry — a stain that grades protein expression as 0, 1+, 2+, or 3+) and FISH (fluorescence in situ hybridization — a test for gene amplification, used for HER2). Markers in active 2026 ADC trials include HER2 (by IHC and FISH; plus the newer HER2-low and HER2-ultra-low designations), TROP2 IHC, B7-H3 IHC, CLDN18.2, CLDN6, PSMA, Nectin-4, and FOLR1. Ask your oncologist for comprehensive testing on archival or fresh biopsy material before evaluating trials.
- Re-biopsy on progression matters. HER2 status changes in 10–20% of patients between primary tumor and metastasis. A fresh biopsy can open ADC trials your initial pathology would have excluded.
- Trial timing peaks at progression. The strongest post-platinum / post-IO enrollment window is right at progression, before too many lines of therapy reduce eligibility. Worth asking about trial options at each decision point, not just at the end.
- ASCO data triggers eligibility shifts. Some trials reset their eligibility criteria within weeks of positive ASCO data — either tightening (to be more selective for the new standard arm) or loosening (to expand into the validated patient population). Check trial postings again 2–3 weeks after the conference.
- Most trials don't mean "placebo or nothing." Phase 3 ADC trials almost always test the new drug added to standard care, or compare two active options head-to-head. You're typically getting at least the standard backbone.
ClinTrialFinder helps you find ADC and other clinical trials matched to your cancer type, biomarkers, and treatment history.
Find ADC Trials for Your Cancer
Disease-Specific Trial Pages
Browse recruiting trials for cancers with active ADC development:
- Breast Cancer Trials — HER2-targeted ADCs, TROP2 ADCs, HER2-low and HER2-ultra-low
- Lung Cancer (NSCLC) Trials — B7-H3, TROP2, HER3, HER2 ADCs
- Nasopharyngeal Carcinoma Trials — EGFR-ADCs (MRG003), bispecific ADCs (BL-B01D1)
- Gastric Cancer Trials — HER2 ADCs, CLDN18.2 ADCs
- HER2+ Gastric Cancer Trials
- Cholangiocarcinoma Trials — HER2-directed ADCs (T-DXd)
- Ovarian Cancer Trials — FOLR1, TROP2, CLDN6 ADCs
- Colorectal Cancer Trials — CDH17, EGFR bispecific ADCs
- Prostate Cancer Trials — PSMA ADCs (ARX517) and STEAP1 ADCs; PSMA radioligand and bispecific TCE trials also active
- Bladder Cancer Trials — Nectin-4 ADCs (enfortumab)
- Merkel Cell Carcinoma Trials
- Browse All Disease Trials
Related Posts
- ADC Therapies at AACR 2026: What Cancer Patients Should Know — the prequel to this preview, covering novel ADC designs presented at AACR.
- T-Cell Engagers at AACR 2026 — bispecific T-cell engager update from April's meeting.
- Immunotherapy and Cell Therapy at AACR 2026
This article previews publicly-anticipated topics for the ASCO 2026 Annual Meeting (May 29 – June 2, Chicago) based on the active Phase 3 trial landscape going into the conference. Specific abstract details will be added after the embargo lifts. This is intended for educational purposes and does not constitute medical advice. Always discuss treatment options with your oncologist.
